Methods: The Phase 3 ADAPT trial was designed to evaluate overall survival (OS) of rocapuldencel-T in combination (Combo) with standard-of-care (SOC) for the treatment of newly diagnosed mRCC as compared to SOC alone (Control). It included adults with synchronous, clear cell mRCC who were eligible for nephrectomy at 107 sites across North America, Europe and Israel.
CITATION STYLE
Figlin, R., Nicolette, C., Tannir, N., Tykodi, S. S., Chen, D., Master, V., … Wood, C. G. (2017). Interim analysis of the phase 3 ADAPT trial evaluating rocapuldencel-T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients with metastatic renal cell carcinoma (mRCC). Annals of Oncology, 28, v404. https://doi.org/10.1093/annonc/mdx376.003
Mendeley helps you to discover research relevant for your work.